Efficacy and safety of rituximab in systemic ...
Document type :
Article dans une revue scientifique: Article de synthèse/Review paper
PMID :
Permalink :
Title :
Efficacy and safety of rituximab in systemic sclerosis: French retrospective study and literature review.
Author(s) :
Thiebaut, Mathilde [Auteur]
Université Pierre et Marie Curie - Paris 6 [UPMC]
Launay, David [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Riviere, Sebastien [Auteur]
Mahevas, Thibaut [Auteur]
Bellakhal, Syrine [Auteur]
Hachulla, Eric [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Fain, Olivier [Auteur]
Mekinian, Arsene [Auteur]
Université Pierre et Marie Curie - Paris 6 [UPMC]
Université Pierre et Marie Curie - Paris 6 [UPMC]
Launay, David [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Riviere, Sebastien [Auteur]
Mahevas, Thibaut [Auteur]
Bellakhal, Syrine [Auteur]
Hachulla, Eric [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Fain, Olivier [Auteur]
Mekinian, Arsene [Auteur]
Université Pierre et Marie Curie - Paris 6 [UPMC]
Journal title :
Autoimmunity Reviews
Abbreviated title :
Autoimmun. Rev.
Volume number :
17
Pages :
582-587
Publication date :
2018-06
Keyword(s) :
Rituximab
Interstitial lung disease
Systemic sclerosis
Interstitial lung disease
Systemic sclerosis
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
Objective: To describe safety and efficacy of rituximab in patients with systemic sclerosis.
Methods: We included 13 patients with systemic sclerosis treated with rituximab and pooled with 40 additional patients from the ...
Show more >Objective: To describe safety and efficacy of rituximab in patients with systemic sclerosis. Methods: We included 13 patients with systemic sclerosis treated with rituximab and pooled with 40 additional patients from the literature. SSc rituximab untreated patients were matched to rituximab treated ones. Results: Thirteen patients who received rituximab and 26 rituximab-untreated patients were included. In comparison to 26 patients who did not received rituximab, FVC changes were not significantly different, whereas DLCO improved in 13 patients who received rituximab (0 [−4; 4] vs loss of −7 [−19; 0]; p = 0.05). Considering 7 rituximab treated and 14 untreated diffuse SSc, FVC was improved during the 24 [12; 46] months of follow up in dSSc who received rituximab (gain of 12 [7.5:14] % vs loss of 1.5 [−16.8; 2.5], (p = 0.003)). Pooled analysis of 53 patients (40 literature patients and 13 from personal series) showed significant improvement of median mRSS from 18 [8; 32] at baseline to 9 [4; 18] at M6 (p = 0.007), 13 [8; 18] at M12 (p = 0.008) and 10 [4; 16] at the last follow-up (p = 0.0002). FVC increased from 71% [66; 80] at baseline to 84% [75; 90] at M12 (p = 0.001). DLCO increased from 58% [39; 65] at M0 to 63% [53; 78] at M12 (p = 0.04). Conclusion: Our personal data and pooled literature analysis suggest the efficacy of rituximab in the subset of diffuse SSc in particular in skin and interstitial disease involvements. The safety of rituximab seems to be reasonable and similar to previous data in other autoimmune diseases.Show less >
Show more >Objective: To describe safety and efficacy of rituximab in patients with systemic sclerosis. Methods: We included 13 patients with systemic sclerosis treated with rituximab and pooled with 40 additional patients from the literature. SSc rituximab untreated patients were matched to rituximab treated ones. Results: Thirteen patients who received rituximab and 26 rituximab-untreated patients were included. In comparison to 26 patients who did not received rituximab, FVC changes were not significantly different, whereas DLCO improved in 13 patients who received rituximab (0 [−4; 4] vs loss of −7 [−19; 0]; p = 0.05). Considering 7 rituximab treated and 14 untreated diffuse SSc, FVC was improved during the 24 [12; 46] months of follow up in dSSc who received rituximab (gain of 12 [7.5:14] % vs loss of 1.5 [−16.8; 2.5], (p = 0.003)). Pooled analysis of 53 patients (40 literature patients and 13 from personal series) showed significant improvement of median mRSS from 18 [8; 32] at baseline to 9 [4; 18] at M6 (p = 0.007), 13 [8; 18] at M12 (p = 0.008) and 10 [4; 16] at the last follow-up (p = 0.0002). FVC increased from 71% [66; 80] at baseline to 84% [75; 90] at M12 (p = 0.001). DLCO increased from 58% [39; 65] at M0 to 63% [53; 78] at M12 (p = 0.04). Conclusion: Our personal data and pooled literature analysis suggest the efficacy of rituximab in the subset of diffuse SSc in particular in skin and interstitial disease involvements. The safety of rituximab seems to be reasonable and similar to previous data in other autoimmune diseases.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
Inserm
Université de Lille
CHU Lille
Université de Lille
CHU Lille
Research team(s) :
Immunity, inflammation and fibrsis in auto and allo-reactivity
Submission date :
2019-03-01T15:24:46Z
2024-01-25T12:37:32Z
2024-01-25T12:37:32Z